Selank vs ARA-290
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Selanc, TP-7
A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
Also: Cibinetide, ARA 290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Selank | ARA-290 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Selank modulates the expression of BDNF (brain-derived neurotrophic factor), influences serotonin and dopamine metabolism, and has effects on the GABAergic system. It also has immunomodulatory properties inherited from its tuftsin backbone. | ARA-290 selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (β common receptor). This receptor is expressed on damaged and inflamed tissues. Activation triggers anti-apoptotic, anti-inflammatory, and tissue-protective pathways without stimulating red blood cell production. |
| Common Dosing | 250-500 mcg intranasal 2-3x daily 2-3x daily, intranasal | 4 mg daily Once daily |
| Administration | Intranasal spray (most common), subcutaneous injection | Subcutaneous injection |
| Typical Duration | 14-21 days typical | 28-day courses in trials |
| Best Time to Take | Morning or as needed for anxiety | Consistent daily timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Russian clinical trials demonstrate anxiolytic effects comparable to benzodiazepines without sedation or addiction potential. Studies show improved cognitive function under stress, enhanced memory, and stabilization of mood. | Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals. |
Frequently Asked Questions: Selank vs ARA-290
What is the difference between Selank and ARA-290?
Selank is a cognitive peptide that a synthetic peptide derived from tuftsin, an immunomodulatory peptide. approved in russia for anxiety and nootropic effects. known for anxiolytic properties without sedation. ARA-290 is a cognitive peptide that an 11-amino acid peptide derived from erythropoietin (epo) that activates the innate repair receptor. unlike epo, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Selank or ARA-290?
Neither is universally "better" - the choice depends on your specific goals. Selank is typically used for cognitive purposes, while ARA-290 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Selank and ARA-290 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Selank and ARA-290 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Selank and ARA-290 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.